Pfizer’s opposition against registration of RUXXIMLA partially successful

European Union

The case confirms that the high degree of attention of the relevant public in respect of goods/services related to the medical field does not automatically rule out the existence of a likelihood of confusion.


Get unlimited access to all WTR content